Compare BNR & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNR | PDSB |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.9M | 49.5M |
| IPO Year | 2020 | N/A |
| Metric | BNR | PDSB |
|---|---|---|
| Price | $23.40 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 54.2K | ★ 563.8K |
| Earning Date | 11-20-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,749,382.00 | N/A |
| Revenue This Year | $136.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.56 | N/A |
| 52 Week Low | $2.18 | $0.70 |
| 52 Week High | $24.92 | $2.20 |
| Indicator | BNR | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 61.39 |
| Support Level | $19.10 | $0.76 |
| Resistance Level | $24.92 | $0.93 |
| Average True Range (ATR) | 2.36 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 67.01 | 82.64 |
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.